Future Outlook for the Primary Osteoarthritis Market: Exploring Novel Pharmacological Interventions and the Impact of Aging Demographics on Disease Modification and Pain Management
Primary Osteoarthritis (OA), the most common form of arthritis and a leading cause of disability worldwide, represents a vast and growing clinical burden, making the Primary Osteoarthritis Market a focal point for pharmaceutical and biotechnology companies. This degenerative joint disease is largely driven by mechanical stress and biochemical factors, predominantly affecting the aging population. The key market driver is the inexorable rise in the elderly demographic globally, coupled with an increasing prevalence of obesity, which places immense, sustained stress on weight-bearing joints such as the knee and hip. Current management strategies primarily revolve around symptomatic relief using NSAIDs, analgesics, and intra-articular injections (corticosteroids and hyaluronic acid), but there is a significant and persistent unmet need for Disease-Modifying Osteoarthritis Drugs (DMOADs) that can slow or halt the structural…